Journal
HUMAN MOLECULAR GENETICS
Volume 19, Issue -, Pages R12-R20Publisher
OXFORD UNIV PRESS
DOI: 10.1093/hmg/ddq160
Keywords
-
Funding
- National Institutes of Health [AG5131, AG11385, AG10435, N544233, AG18440]
Ask authors/readers for more resources
Alzheimer's disease (AD) is characterized by cognitive impairment, progressive neurodegeneration and formation of amyloid-beta (A beta)-containing plaques and neurofibrillary tangles composed of hyperphosphorylated tau. The neurodegenerative process in AD is initially characterized by synaptic damage accompanied by neuronal loss. In addition, recent evidence suggests that alterations in adult neurogenesis in the hippocampus might play a role. Synaptic loss is one of the strongest correlates to the cognitive impairment in patients with AD. Several lines of investigation support the notion that the synaptic pathology and defective neurogenesis in AD are related to progressive accumulation of A beta oligomers rather than fibrils. Abnormal accumulation of A beta resulting in the formation of toxic oligomers is the result of an imbalance between the levels of A beta production, aggregation and clearance. A beta oligomers might lead to synaptic damage by forming pore-like structures with channel activity; alterations in glutamate receptors; circuitry hyper-excitability; mitochondrial dysfunction; lysosomal failure and alterations in signaling pathways related to synaptic plasticity, neuronal cell and neurogenesis. A number of signaling proteins, including fyn kinase; glycogen synthase kinase-3 beta (GSK3 beta) and cyclin-dependent kinase-5 (CDK5), are involved in the neurodegenerative progression of AD. Therapies for AD might require the development of anti-aggregation compounds, pro-clearance pathways and blockers of hyperactive signaling pathways.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available